Methyl-CpG-binding domain 2 mitigates osteoarthritis through Steap3 promoter methylation and chondrocyte ferroptosis...

Area of Science:

• Epigenetics
• Molecular Biology
• Disease Pathogenesis

Background:

• Osteoarthritis (OA) is a debilitating joint disease influenced by DNA methylation.
• Methyl-CpG-binding domain 2 (MBD2) is a critical DNA methylation reader involved in inflammatory diseases.
• The specific role of MBD2 in OA pathogenesis remains largely unexplored.

Purpose of the Study:

• To investigate the role of MBD2 in osteoarthritis (OA) development.
• To elucidate the underlying molecular mechanisms by which MBD2 influences OA.
• To assess the therapeutic potential of targeting MBD2 in OA.

Main Methods:

• Analysis of MBD2 expression in human and mouse OA cartilage.
• Chondrocyte-specific Mbd2 knockout mouse model to study OA progression.
• RNA sequencing to identify MBD2-regulated pathways.
• Chromatin accessibility (CUT&Tag) and bisulfite sequencing to determine MBD2 binding and DNA methylation targets.
• In vivo interventions using ferroptosis inhibitors and gene therapy (AAV-mediated knockdown/overexpression).

Main Results:

• MBD2 expression was elevated in OA cartilage, but nuclear import was reduced.
• Mbd2 knockout in chondrocytes exacerbated OA and induced ferroptosis.
• MBD2 deletion led to increased Steap3 promoter methylation and subsequent ferroptosis.
• Inhibition of ferroptosis or Steap3 knockdown ameliorated OA in Mbd2 knockout mice.
• Overexpression of MBD2 partially protected against OA progression.

Conclusions:

• MBD2 is a crucial regulator in OA pathogenesis, acting via DNA methylation to suppress ferroptosis in chondrocytes.
• MBD2 levels and function are critical for maintaining cartilage integrity.
• Targeting MBD2 presents a promising therapeutic avenue for osteoarthritis treatment.